Epstein Secrets

place statins," says Schliefer, the Regeneron CEO. Most people who have muscle problems from statins do not have those elevated muscle enzymes, says Nissen, the Cleveland Clinic cardiologist, who is conducting a clinical trial Amgen and Pfizer, which is also developing a similar cholesterol drug. He sa

were halted pending news. But doctors may prescribe the drug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had

at patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven HOUSE_OVERSIGHT_025888 --- PAGE BREAK --- Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical offi

y were halted pending news. But doctors may prescribe the drug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had h

in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical offi

y were halted pending news. But doctors may prescribe the drug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had h